{
    "root": "34b19a23-4595-417e-9592-fd1d69398e59",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Spironolactone",
    "value": "20250301",
    "ingredients": [
        {
            "name": "Spironolactone",
            "code": "27O7W4T232"
        },
        {
            "name": "Calcium Sulfate Dihydrate",
            "code": "4846Q921YM"
        },
        {
            "name": "Hypromellose, Unspecified",
            "code": "3NXW29V3WO"
        },
        {
            "name": "Magnesium Stearate",
            "code": "70097M6I30"
        },
        {
            "name": "Microcrystalline Cellulose 101",
            "code": "7T9FYH5QMK"
        },
        {
            "name": "Mint",
            "code": "FV98Z8GITP"
        },
        {
            "name": "Polyethylene Glycol, Unspecified",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "Povidone K30",
            "code": "U725QWY32X"
        },
        {
            "name": "Starch, Corn",
            "code": "O8232NY3SJ"
        },
        {
            "name": "Sodium Starch Glycolate Type A Potato",
            "code": "5856J3G2A2"
        },
        {
            "name": "Talc",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "Titanium Dioxide",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "spironolactone aldosterone antagonist indicated : \u2022 treatment nyha class iii-iv heart failure reduced ejection fraction increase survival , manage edema , reduce need hospitalization heart failure ( error ! hyperlink reference valid . ) . \u2022 add-on therapy treatment hypertension , lower blood pressure . lowering blood pressure reduces risk fatal nonfatal cardiovascular events , primarily strokes myocardial infarctions ( error ! hyperlink reference valid . ) . \u2022 management edema adult patients cirrhotic edema responsive fluid sodium restrictions setting nephrotic syndrome treatment underlying disease , restriction fluid sodium intake , diuretics produce inadequate response ( 1.3 ) . \u2022 treatment primary hyperaldosteronism : ( 1.4 ) short-term preoperative treatment long-term maintenance patients discrete aldosterone-producing adrenal adenomas candidates surgery patients bilateral micro macronodular adrenal hyperplasia",
    "contraindications": "\u2022 heart failure : initiate treatment 25 mg daily ( error ! hyperlink reference valid . ) . \u2022 hypertension : initiate treatment 25 100 mg daily either single divided doses ( error ! hyperlink reference valid . ) . \u2022 edema : initiate therapy hospital setting titrate slowly . recommended initial daily dose 100 mg single divided doses ( error ! hyperlink reference valid . ) . \u2022 primary hyperaldosteronism : initiate treatment 100 400 mg preparation surgery . patients unsuitable surgery lowest effective determined individual patient ( error ! hyperlink reference valid . ) .",
    "warningsAndPrecautions": "spironolactone 100 mg tablets round , white off-white , scored , convex , coated , debossed 854 bisect one side debossed \u201c \u201d side , supplied : ndc number size 82804-205-30 bottle 30 store 77\u00b0f ( 25\u00b0c ) .",
    "adverseReactions": "spironolactone contraindicated patients : \u2022 hyperkalemia \u2022addison \u2019 disease \u2022concomitant eplerenone",
    "indications_original": "Spironolactone is an aldosterone antagonist indicated for: \u2022 The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( Error! Hyperlink reference not valid. ). \u2022 Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( Error! Hyperlink reference not valid. ). \u2022 The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). \u2022 Treatment of primary hyperaldosteronism for: ( 1.4 ) o Short-term preoperative treatment o Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia",
    "contraindications_original": "\u2022 Heart Failure: Initiate treatment at 25 mg once daily ( Error! Hyperlink reference not valid. ). \u2022 Hypertension: Initiate treatment at 25 to 100 mg daily in either single or divided doses ( Error! Hyperlink reference not valid. ). \u2022 Edema:\u00a0 Initiate therapy in a hospital setting and titrate slowly.\u00a0 The recommended initial daily dose is 100 mg in single or divided doses ( Error! Hyperlink reference not valid. ). \u2022 Primary hyperaldosteronism:\u00a0 Initiate treatment at 100 to 400 mg in preparation for surgery.\u00a0 In patients unsuitable for surgery use the lowest effective dosage determined for the individual patient ( Error! Hyperlink reference not valid. ).",
    "warningsAndPrecautions_original": "Spironolactone 100 mg tablets are round, white to off-white, scored, convex, coated, debossed with 854 above of the bisect on one side and debossed with \u201cO\u201d on the other side, supplied as:\n                  \n                     \n                     \n                     \n                        \n                           \n                              NDC Number\n                           \n                           \n                              Size\n                           \n                        \n                        \n                           \n                              82804-205-30\n                           \n                           \n                              bottle of 30\n                           \n                        \n                        \n                           \n                           \n                        \n                     \n                  \n                  Store below 77\u00b0F (25\u00b0C).",
    "adverseReactions_original": "Spironolactone is contraindicated in the patients with:\n                  \n                     \n                        \u2022\n                        Hyperkalemia\n                     \n                     \n                        \u2022Addison\u2019s disease\n                     \n                        \u2022Concomitant use of eplerenone"
}